The path of breast-to-brain cancer metastasis

The path of breast-to-brain cancer metastasis
Breast cancer cells (blue) associate with glutamate-secreting neurons (red) to stimulate NMDA receptor-mediated signaling (green) of tumor growth. (STED super-resolution microscopy). Credit: W. Jiao and Q. Zeng (EPFL)

In 2018, breast cancer was the most common cancer in women worldwide, accounting for about a quarter of all reported cancers. When breast cancer metastasizes, the brain is a common destination.

The prevalence of breast-to- has led scientists to suspect that there is an underlying rationale for why seek out and seed tumor growths in the brain. Elucidating the rationale might give us the means to minimize breast-to-brain metastases or even prevent them altogether.

Publishing in Nature, scientists at EPFL's Swiss Institute for Experimental Cancer Research (ISREC) have discovered that this process involves the N-methyl-D-aspartate receptor (NMDAR), which is found on the cell membranes of neurons and is involved in the transmission of nerve impulses. The NMDAR is activated by the amino acid glutamate, released from pre-synaptic neurons during synaptic transmission of such impulses.

The ISREC group has shown in the past that glutamate-stimulated NMDAR signaling helps both neuroendocrine and ductal pancreatic tumors grow invasively, and that this co-opted neuronal signaling circuit is generally associated with a poor treatment prognosis in a variety of cancer types. So when the researchers began looking for suspects in breast-to-brain metastases, the NMDAR was at the top of the list.

The investigation paid off: The researchers grew breast-to-brain metastasis cells in the lab to study their relationship to the NMDAR. And, sure enough, the cells were found to co-opt the entire system by which the NMDAR relays its effects to neurons—what biologists refer to as a "signaling pathway."

It seems that a key to metastasizing to the brain involves turning on the NMDAR. Although some secrete sufficient glutamate to auto-activate NMDAR, the current study found that it's not sufficient in breast cancer cells. So, how might they activate the NMDAR receptor?

In a breakthrough discovery, the researchers found that the breast cancer cells form "fake" synapses with the neurons that normally secrete glutamate as a neurotransmitter. The synapse is "pseudo-tripartite" because it resembles the tripartite synapse between two neurons and the surrounding non-neuronal, supporting cells (e.g. astrocytes).

Once the synapses are formed, the neurons supply the breast-cancer cells with ample glutamate, and the NMDAR receptor turns on, providing what the authors call "an insidious rationale for brain metastasis."

"This remarkable mechanism for fueling the growth of metastatic tumors in the brain adds to an expanding about the parameters of metastasis that we hope will be applicable to prevention and therapy," says Douglas Hanahan. "The challenge is the insidious proximity of the cells to normal neuronal synapses, for which NMDAR signaling is crucial. Thus, in future research, we and others will need to search for specific vulnerabilities in glutamate-fueled metastatic that can be targeted therapeutically to block brain metastasis, while sparing the adjacent normal neurons."

Explore further

Researchers provide definitive proof for receptor's role in synapse development

More information: Synaptic proximity enables NMDAR signalling to promote brain metastasis, Nature (2019). DOI: 10.1038/s41586-019-1576-6 ,
Journal information: Nature

Citation: The path of breast-to-brain cancer metastasis (2019, September 18) retrieved 17 August 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors